Bioptimus
AI-driven tool accelerating biological research with predictive analytics.. [Contact for Pricing]
Last verified:
What is Bioptimus?
Bioptimus builds multimodal foundation models that connect biological data across scales (molecule, cell, tissue, organ) to predict biological outcomes and accelerate biomedical discovery. The platform offers pre-trained models (notably H-Optimus for pathology and M-Optimus for multi-modal biology) plus a data engine (STELA) that aggregates deeply profiled, clinically-linked patient datasets to enable model training and downstream analyses. Key capabilities include histology-to-spatial prediction, integration of histology with spatial transcriptomics and genomics, biomarker and drug-target discovery from archived clinical data, and tools to score archival cohorts to inform indication expansion and trial design. Bioptimus is aimed at pharma and biotech R&D teams, translational researchers, diagnostic developers, and clinical research organizations that need multimodal biological representations to boost target selection, patient stratification, and trial success probability.
Bioptimus pricing
Pricing model: Freemium
The website does not publish standard consumer-style tiers; Bioptimus presents its offering as enterprise- and collaboration-focused with model access (H-Optimus, M-Optimus) and data collaboration (STELA) available through direct engagement. There is no clearly listed free self-serve tier visible on the homepage; pricing and plan details (including any pilot, subscription, or per-project fees) are provided through direct contact or partnership discussions rather than public pricing pages.
Bioptimus pros
- Multimodal models that learn jointly across cell-to-organ scales
- H-Optimus pathology model with benchmark-leading performance
- M-Optimus integrates pathology, spatial transcriptomics, and genomics
- Designed to score archival H&E slides without new assays
- STELA data engine provides clinically linked, deeply profiled patient data
- Proven use cases across drug target and biomarker discovery
- Validated in independent benchmarks and peer-reviewed studies
- Trusted by 16 of the top 20 pharma companies
- Over 1,000 institutions reported as users
- High total model downloads and published papers supporting adoption
- Works with small early-phase cohorts to find multimodal biomarkers
- Can predict spatial distribution of ADC drug targets from routine histology
- Supports indication expansion by scoring cohorts across diseases and stages
- Integrates existing sequencing and clinical records with histology
- Offers case studies with real-world implementations at major research centers
Bioptimus cons
- No publicly displayed self-serve free tier or detailed public pricing on the homepage
- Enterprise focus may limit accessibility for small labs or individual researchers
- Heavy reliance on institutional data-sharing (STELA) which requires collaboration
- Primary emphasis on pathology and spatial biology—less clear support for other assay modalities
- Integration and deployment details (APIs, on-prem vs cloud) not fully documented on site
- Regulatory/clinical validation pathways for model outputs are not described in detail
- Requires existing archived digital pathology and sequencing infrastructure to maximize value
- Technical requirements and compute costs for large-scale multimodal training are not specified
Frequently asked questions about Bioptimus
What models does Bioptimus offer and what do they do?
Bioptimus publishes foundation models including H-Optimus (a pathology-focused foundation model) and M-Optimus (a multimodal model integrating pathology, spatial transcriptomics, and genomics); H-Optimus is optimized for histology tasks and benchmarked against public pathology datasets, while M-Optimus is built to produce unified biological representations across modalities for target discovery and patient stratification.
Who is Bioptimus intended for?
Bioptimus targets pharmaceutical and biotech R&D teams, translational researchers, diagnostics developers, and clinical research organizations that need multimodal biological representations to discover targets, derive biomarkers, score archival cohorts, and design higher-probability clinical trials.
What is STELA and how does it work?
STELA is Bioptimus’s multi-institutional data engine that aggregates deeply profiled, clinically linked, multimodal patient data across geographies and disease areas; institutions contribute and benefit from the atlas, which supplies scale and diversity needed to train foundation models and generate clinically actionable outputs.
Can Bioptimus analyze archival H&E slides without new assays?
Yes — Bioptimus emphasizes the ability to predict spatial biology signals (for example ADC targets, immune microenvironment features, and stromal architecture) directly from routine histology slides, enabling organizations to extract value from existing archived slide repositories without performing new wet-lab assays.
Has Bioptimus been validated independently?
The site states their models hold top ranks on industry-standard public benchmarks, are validated by independent teams, and have been used in peer-reviewed research and multiple case studies with major institutions, indicating external validation and real-world applicability.
How does Bioptimus support trial design and treatment response prediction?
Bioptimus’s multimodal models discover biomarker signatures that distinguish responders from non-responders using integrated histology, sequencing, and clinical data, allowing sponsors to score cohorts, refine inclusion criteria, and increase probability of success before late-phase trials.
What data do I need to use Bioptimus models effectively?
To maximize value you should have digital histology (H&E) slides, sequencing data and linked clinical records; these existing archives are what Bioptimus uses to derive multimodal signatures and to score cohorts across disease, stage, and mechanism.
Is pricing available directly on the website?
No; the website positions Bioptimus as an enterprise partner and requests direct engagement for access and pricing information rather than listing public subscription tiers or per-seat pricing on the homepage.
Can small labs or academic groups access Bioptimus models?
The site emphasizes collaboration and multi-institutional data contributions through STELA and highlights enterprise-scale partnerships; while academic collaborations and research use are referenced via publications and community contacts, there is no clearly displayed self-serve or low-cost plan on the public site, so access would likely require direct outreach or partnership.
How does Bioptimus handle multi-modal integration technically?
Bioptimus states its models are trained natively across modalities and scales—jointly learning cross-modal patterns from histology, spatial transcriptomics, and genomics so the architecture can predict downstream biology (e.g., spatial distributions and multimodal biomarkers) rather than treating each data type in isolation.